文献速递产科

Tafoxiparin——一种用于宫颈成熟和引产辅助的新型候选药物:两项随机安慰剂对照研究结果

Tafoxiparin, a novel drug candidate for cervical ripening and labor augmentation: results from 2 randomized, placebo-controlled studies.
PubMed 文献 · Am J Obstet Gynecol · 2023-05-17

两项随机双盲安慰剂对照Ⅱ期研究评估Tafoxiparin在初产妇中的效果。研究1在临产前皮下给药,主要终点无显著差异,但宫缩时间超过12小时的风险显著降低(Tafoxiparin组6/114[5%] vs 安慰剂组18/101[18%],P=.0045)。研究2静脉给药辅助缩宫素未影响主要终点。两研究均提示母婴安全性良好。

要点

  • 临产前皮下注射Tafoxiparin可降低宫缩时间超过12小时的风险(5% vs 18%,P=.0045)
  • 引产产妇中Tafoxiparin组中位宫缩时间4.44小时 vs 安慰剂组7.03小时(P=.0041)
  • 研究2静脉Tafoxiparin辅助缩宫素对主要及次要终点均无显著影响

核心结论

  • 临产前皮下Tafoxiparin可能有效缩短引产产妇及因产程进展缓慢需缩宫素者的宫缩时间,并可能对宫颈成熟有正面作用。
  • 产程停滞患者短期静脉Tafoxiparin辅助缩宫素未影响宫缩时间或其他终点。
  • 两项研究均提示Tafoxiparin对母婴安全性良好。

研究设计与样本

  • 研究1为探索性首次妊娠妇女研究,研究2为剂量探索研究,均为随机双盲安慰剂对照Ⅱ期临床研究。
  • 研究对象为18至45岁健康初产妇,正常单胎妊娠,超声确认孕周。
  • 研究1随机263例,孕38至40周每日皮下注射60 mg Tafoxiparin或安慰剂0.4 mL直至临产(最长28天)。
  • 研究2随机361例,因产程进展缓慢、潜伏期延长或产程停滞,在接受缩宫素同时接受安慰剂或3种短期Tafoxiparin方案之一(初始负荷7、21或35 mg,随后持续输注5、15或25 mg/小时直至分娩;最长36小时)。

主要发现

  • 两研究主要终点在Tafoxiparin与安慰剂间均无统计学显著差异。
  • 研究1中宫缩时间超过12小时的风险Tafoxiparin组6/114(5%)vs安慰剂组18/101(18%),P=.0045。
  • 事后分析:引产产妇中位(范围)宫缩时间Tafoxiparin组4.44(1.2-8.5)小时 vs 安慰剂组7.03(1.5-14.3)小时,P=.0041。
  • 引产产妇中Tafoxiparin对宫颈成熟有正面作用11/13例(85%)vs安慰剂组3/13例(23%),P=.004;因产程进展缓慢需缩宫素者相应为34/51例(66%)vs 16/40例(40%),P=.004。
  • 研究2中Tafoxiparin对次要终点无正面影响;除研究1注射部位反应外,母婴不良事件未比安慰剂更常见,严重或治疗相关不良事件少。

临床怎么用

  • 作者认为临产前皮下Tafoxiparin可能有效缩短引产及因产程进展缓慢需缩宫素者的宫缩时间,并可能对宫颈成熟有正面作用。
  • 作者报告产程停滞患者短期静脉Tafoxiparin辅助缩宫素未影响宫缩时间或其他终点。
  • 作者报告两研究均提示Tafoxiparin对母婴安全性良好。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Slow progression of labor is a common obstetrical problem with multiple associated complications. Tafoxiparin is a depolymerized form of heparin with a molecular structure that eliminates the anticoagulant effects of heparin. We report on 2 phase II clinical studies of tafoxiparin in primiparas. Study 1 was an exploratory, first-in-pregnant-women study and study 2 was a dose-finding study. OBJECTIVE: Study 1 was performed to explore the effects on labor time of subcutaneous administration of tafoxiparin before onset of labor. Study 2 was performed to test the hypothesis that intravenous treatment with tafoxiparin reduces the risk for prolonged labor after spontaneous labor onset in situations requiring oxytocin stimulation because of dystocia. STUDY DESIGN: Both studies were randomized, double-blind, and placebo-controlled. Participants were healthy, nulliparous females aged 18 to 45 years with a normal singleton pregnancy and gestational age confirmed by ultrasound. The primary endpoints were time from onset of established labor (cervical dilation of 4 cm) until delivery (study 1) and time from start of study treatment infusion until delivery (study 2). In study 1, patients at 38 to 40 weeks of gestation received 60 mg tafoxiparin or placebo daily as 0.4 mL subcutaneous injections until labor onset (maximum 28 days). In study 2, patients experiencing slow progression of labor, a prolonged latent phase, or labor arrest received a placebo or 1 of 3 short-term tafoxiparin regimens (initial bolus 7, 21, or 35 mg followed by continuous infusion at 5, 15, or 25 mg/hour until delivery; maximum duration, 36 hours) in conjunction with oxytocin. RESULTS: The number of participants randomized in study 1 was 263, and 361 were randomized in study 2. There were no statistically significant differences in the primary endpoints between those receiving tafoxiparin and those receiving the placebo in both studies. However, in study 1, the risk for having a labor time exceeding 12 hours was significantly reduced by tafoxiparin (tafoxiparin 6/114 [5%] vs placebo 18/101 [18%]; P=.0045). Post hoc analyses showed that women who underwent labor induction had a median (range) labor time of 4.44 (1.2-8.5) hours with tafoxiparin and 7.03 (1.5-14.3) hours with the placebo (P=.0041) and that co-administration of tafoxiparin potentiates the effect of oxytocin and facilitates a shorter labor time among women with a labor time exceeding 6 to 8 hours (P=.016). Among women induced into labor, tafoxiparin had a positive effect on cervical ripening in 11 of 13 cases (85%) compared with 3 of 13 participants (23%) who received the placebo (P=.004). For women requiring oxytocin because of slow progression of labor, the corresponding results were 34 of 51 participants (66%) vs 16 of 40 participants (40%) (P=.004). In study 2, tafoxiparin had no positive effects on the secondary endpoints when compared with the placebo. Except for injection-site reactions in study 1, adverse events were no more common for tafoxiparin than for the placebo among either mothers or infants. There were few serious or treatment-related adverse events. CONCLUSION: Subcutaneous treatment with tafoxiparin before labor onset (study 1) may be effective in reducing the labor time among women undergoing labor induction and among those requiring oxytocin for slow progression of labor. Moreover, tafoxiparin may have a positive effect on cervical ripening. Short-term, intravenous treatment with tafoxiparin as an adjunct to oxytocin in patients with labor arrest (study 2) did not affect labor time or other endpoints. Both studies suggest that tafoxiparin has a favorable safety profile in mothers and their infants.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Ekman-Ordeberg G, Hellgren-Wångdahl M, Jeppson A, et al. Tafoxiparin, a novel drug candidate for cervical ripening and labor augmentation: results from 2 randomized, placebo-controlled studies. Am J Obstet Gynecol. 2023. PMID: 38462256. doi:10.1016/j.ajog.2022.10.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。